August 10, 2005 -- When the IPO window opened in October 2003, after being shut for almost a year and a half, 21 biotech companies managed to go public before another slowdown hit in April of 2004. Most of the 21 managed to price in a reasonable range ($12-14), especially those early out of the blocks, although prices were often down from initial requests. Compared to earlier ventures, these companies were considered relatively safe. But how did they do? We take a look at the results...
